Neutrophil-to-albumin ratio: a promising tool for CAD assessment in non-ST elevation AMI

dc.contributor.authorKarasu, M.
dc.contributor.authorKaraca, Y.
dc.contributor.authorYildirim, E.
dc.contributor.authorKobat, M. A.
dc.contributor.authorEr, F.
dc.date.accessioned2026-08-12T16:58:06Z
dc.date.issued2023
dc.departmentFırat Üniversitesi
dc.description.abstractOBJECTIVE: In the context of coronary artery disease (CAD) pathogenesis, inflammation has emerged as a critical player. This study investigates the potential of the Neutrophil-to-Albumin Ratio (NAR) as a novel bio-marker for assessing CAD severity and extension in patients suffering from acute myocardial infarction (AMI) without ST-segment elevation.PATIENTS AND METHODS: We conducted a comprehensive analysis of consecutive patient records (n = 211) from a single center, focusing on individuals diagnosed with non-ST elevation AMI. To gauge CAD severity, we employed Syntax Scores (SS) and examined their correlation with NAR, C-reactive protein-albumin ratio (CRPALB), and the systemic immune inflammation index (SII). Statistical analyses were conducted to establish associations and predictive capabilities.RESULTS: Our analysis revealed a significant correlation between NAR and Syntax Scores (r: .416, p<0.01). Notably, patients with intermediate-high SS exhibited significantly elevated NAR values com-pared to those in the low SS group [20.86+5.38 vs. 16.41+6.30 (p<0.001)]. Furthermore, NAR outper-formed CRPALB, SII, and Neutrophil Percent-to -Albu-min Ratio (NPAR) in discriminating CAD severity, as demonstrated by the Receiver Operating Character -istic (ROC) curve analysis (NAR AUC: 0.736; CRPALB AUC: 0.673; SII AUC: 0.660; NPAR AUC: 0.717).CONCLUSIONS: This study underscores the potential of NAR as a robust predictor of CAD se-verity and extension in non-ST elevation AMI pa-tients. While previous markers, such as CRPALB and SII, are advantageous, NAR's superior pre-dictive capabilities are a valuable addition to the clinician's toolkit, offering enhanced risk assess-ment for this specific patient subgroup.
dc.identifier.endpage11839
dc.identifier.issn1128-3602
dc.identifier.issue24
dc.identifier.orcid0000-0003-1713-3451
dc.identifier.orcid0000-0002-5016-5511
dc.identifier.pmid38164846
dc.identifier.scopus2-s2.0-85180987365
dc.identifier.scopusqualityN/A
dc.identifier.startpage11832
dc.identifier.urihttps://hdl.handle.net/11508/46730
dc.identifier.volume27
dc.identifier.wosWOS:001147600800007
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherVerduci Publisher
dc.relation.ispartofEuropean Review for Medical and Pharmacological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectNeutrophil-to-albumin ratio
dc.subjectNon-ST elevated myocardial infarction
dc.subjectSYNTAX score
dc.titleNeutrophil-to-albumin ratio: a promising tool for CAD assessment in non-ST elevation AMI
dc.typeArticle

Dosyalar